Alkermes inks rich collaboration deal for Vivitrex

Cephalon has agreed to pay Alkermes $160 million up front and another $110 million on the approval of Vivitrex for alcohol dependence. Cambridge, Massachusetts-based Alkermes filed an NDA for Vivitrex on March 31. Cephalon also agreed to pay up to $220 million for hitting certain sales goals once the drug is on the market.

"In creating and building new markets for Provigil, we have established a proven track record of launching and growing innovative products," said Frank Baldino, Jr., PhD, chairman and CEO of Cephalon. "We believe the characteristics of the alcohol dependence market parallel those we encountered when we first launched Provigil to treat excessive sleepiness."

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.